BCYC News and Press, Bicycle Therapeutics plc From 06/08/22

Completed Phase I dose escalation; results expected in 3Q22 Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today annou...

Interest rates are rising, and this article discusses the BDC sector currently yielding between 7% and 12% that will benefit. This article discusses HTGC currently yielding over 12% for the reasons discussed below and will likely rebound, providing excellent returns. HTGC is well ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that management will participate in a fireside chat at the Jefferie...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that the company will present a Trials in Progress poster highlight...

Piper Sandler cut its price target (PT) on 17 companies in the biotech space reflecting the recent pullback in the stock and prevailing market conditions. Piper Sandler also noted that biotech valuations have re-rated. Following are the stocks which saw their PT lowered: Gene editing com...

Bicycle Therapeutics press release (NASDAQ:BCYC): Q1 GAAP EPS of -$0.93 misses by $0.26. Revenue of $3.86M (+113.3% Y/Y) misses by $0.55M. CEO comment: “Beyond our Bicycle Toxin Conjugates®, or BTCs, we continue to be encouraged as we progress our Bicycle TICA™ programs for...

- Continued clinical progress across pipeline, including interim BT8009 Phase I clinical data - Cash and cash equivalents of $407.4 million as of March 31, 2022 expected to provide financial runway through 2024 Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology...

Bicycle reported updated interim data from their lead cancer program, BT8009. Preliminary data suggestive of it being effective against solid tumors. Patients in the 5.0mg/m2 weekly BT8009 cohort showed a 50% overall response rate with favorable tolerability. The market’s i...

Stocks rebounded from recent weakness on Wednesday, as bargain hunting among beaten-down growth stocks pushed the major averages higher. The Nasdaq led the advance, climbing about 2% on the day. Travel stocks contributed to the upswing. An upbeat earnings report from Delta Air Lines raised ho...

B. Riley analyst Kalpit Patel downgraded Bicycle Therapeutics (BCYC -4.3%) to Neutral from Buy with a price target of $33, down from $62, after speaking to a physician-scientist focused on treating patients with genitourinary malignancies. The doctor was unsure of BT8009's regulatory path and...